Skip to main content

4 Result(s)

within Philippe Rougier Remove this filter Internal Medicine Remove this filter

and

  1. No Access

    Article

    Irinotecan as palliative chemotherapy for metastatic colorectal cancer: evolving tactics following initial treatment

    Patients with metastatic colorectal cancer (mCRC) who progress despite treatment with fluoropyrimidine and irinotecan or oxaliplatin have diminished survival, but they may derive clinically meaningful benefit ...

    Emmanuel Mitry, Astrid Lièvre… in International Journal of Colorectal Disease (2009)

  2. No Access

    Article

    Meta-Analysis of Randomised Trials Comparing Gemcitabine-Based Doublets versus Gemcitabine Alone in Patients with Advanced and Metastatic Pancreatic Cancer

    Objective: To evaluate the impact on overall survival at 6, 12 and 18 months of gemcitabine-based doublets compared with gemcitabine alone in patients with advanced and metastatic pancreatic canc...

    Dr Eugeniu Banu, Adela Banu, Andrei Fodor, Bruno Landi, Philippe Rougier… in Drugs & Aging (2007)

  3. No Access

    Article

    No evidence of somatic FGFR3 mutation in various types of carcinoma

    Germline specific point mutations in the gene encoding fibroblast growth factor receptor 3 (FGFR3) are associated with autosomal dominant human skeletal dysplasia and craniosynostosis syndromes. Mutations iden...

    Mehdi Karoui, Hélène Hofmann-Radvanyi, Ute Zimmermann, Anne Couvelard… in Oncogene (2001)

  4. No Access

    Article

    Oral diclofenac combined with intra-portal pirarubicin: increased efficacy on liver VX2 tumour and hepatotoxicity in rabbits

    VX2 is a carcinoma established in rabbits and producing an autocrine growth factor, prostaglandin E2. Pirarubicin is a potent anti-VX2 agent. We investigated whether the oral intake of enprostil—a synthetic prost...

    Bruno Donatini, Caroline Bognel… in Journal of Cancer Research and Clinical On… (1994)